The stockholders letter is irrelevant. 175 mil
Post# of 154065
(Total Views: 802)
Posted On: 12/10/2020 1:34:11 AM
The stockholders letter is irrelevant.
175 million shares and that's the best idea the group can offer?
Patterson is a brilliant scientist. But at this point he has no impact on the CD12 study results. He can't change anything.
His inclusion at this 11th hour in the hopes of persuading the FDA to approve LL would be a hail mary more than anything else.
If LL is approved for covid, $2 billion drops straight into Cytodyn's bank account.
Cytydyn will definitely need a strategy for research and development if the $2 billion drops straight into Cutodyn's bank accounts.
While Patterson could help with R&D strategies, especially clinical trial endpoint design, Patterson's help is not mission critical in the event of covid approval. There will be far bigger problems. Whatever team they can put together will have to work together. Cytodyn has no experience managing any effort of any significant size, which is what they will quickly have with $2 billion in the bank. If Patterson brings team anxiety, his presence will be detrimental rather than helpful.
If not approved for covid, Cytodyn has a cash flow problem that they need to fix.
Patterson can't help with that either.
Cytodyn has a massively binary event coming up very soon. Throwing Patterson into the mix at the 11th hour is not going to help with anything.
Patterson is a disciplined, thoughtful contributor. His impact is long term. Cytodyn can't make any long term plans until Cytodyn sorts through their upcoming massively binary events.
A large shareholder group sending Patterson letters is a distraction and a waste of everyone's time at this moment.
175 million shares and that's the best idea the group can offer?
Patterson is a brilliant scientist. But at this point he has no impact on the CD12 study results. He can't change anything.
His inclusion at this 11th hour in the hopes of persuading the FDA to approve LL would be a hail mary more than anything else.
If LL is approved for covid, $2 billion drops straight into Cytodyn's bank account.
Cytydyn will definitely need a strategy for research and development if the $2 billion drops straight into Cutodyn's bank accounts.
While Patterson could help with R&D strategies, especially clinical trial endpoint design, Patterson's help is not mission critical in the event of covid approval. There will be far bigger problems. Whatever team they can put together will have to work together. Cytodyn has no experience managing any effort of any significant size, which is what they will quickly have with $2 billion in the bank. If Patterson brings team anxiety, his presence will be detrimental rather than helpful.
If not approved for covid, Cytodyn has a cash flow problem that they need to fix.
Patterson can't help with that either.
Cytodyn has a massively binary event coming up very soon. Throwing Patterson into the mix at the 11th hour is not going to help with anything.
Patterson is a disciplined, thoughtful contributor. His impact is long term. Cytodyn can't make any long term plans until Cytodyn sorts through their upcoming massively binary events.
A large shareholder group sending Patterson letters is a distraction and a waste of everyone's time at this moment.
(13)
(1)